APS Foundation of America, Inc.

10/30/2026

For years, education has understandably concentrated on blood clots, , and laboratory testing. Your research helps document another important part of the disease: what living with APS actually feels like.

, brain fog, pain, disrupted sleep, and difficulty participating in everyday activities deserve attention in clinical care, too.

Because this cross-sectional study used self-reported APS diagnoses, it establishes associations rather than proving that APS directly caused every reported impairment. Still, the findings strongly justify further investigation and more patient-centered assessments.

“The APS Foundation of America ( ) is proud to have collaborated on this international research study by helping recruit participants. We are also pleased to be involved in the next phase of this important research into the quality-of-life challenges experienced by people living with Syndrome.”

Read the full article: https://www.sciencedirect.com/science/article/pii/S2475037926029341

10/28/2026

High-Risk Pregnancies in Women With APS, Lupus May Soon See Upgrade in Standard of Care

New research suggests that adding a biologic medication called certolizumab pegol ( ) to standard treatment may significantly improve pregnancy outcomes in women with Syndrome ( ), including those who also have ( ).

The phase 2 IMPACT trial, led by researchers including Dr. Jane E. Salmon of Hospital for Special Surgery ( ), investigated whether blocking inflammation with a TNF-alpha inhibitor could reduce serious pregnancy complications.
Researchers found that adding certolizumab to standard treatment was associated with a more than 50% reduction in adverse pregnancy outcomes compared with historical controls.

Among the original 45 pregnancies studied, 93% resulted in babies surviving to hospital discharge. An additional 10 pregnancies have since been included, all resulting in surviving infants, bringing the overall survival-to-discharge rate to approximately 95%.

Why This Research Matters
Standard treatment for obstetric APS often includes low-dose aspirin and heparin to reduce blood clotting risks. However, some women continue to experience pregnancy complications despite treatment.

This research suggests that inflammation, not just blood clotting, plays an important role in APS-related pregnancy complications.

By targeting inflammation, certolizumab may offer an additional treatment option for women at particularly high risk of pregnancy loss, preeclampsia, premature delivery, and placental complications.

Important Limitations
Although the results are encouraging, the IMPACT trial was relatively small and did not include a randomized control group. Researchers compared outcomes with historical controls, meaning the findings cannot definitively establish that certolizumab caused the improvements.

Certolizumab is also not currently approved specifically to prevent APS-related pregnancy complications. Additional research is needed before it can be recommended as routine treatment for obstetric APS.

Key Takeaway: The IMPACT trial represents a promising advancement in APS pregnancy research. Targeting inflammation alongside traditional anticoagulation may help improve outcomes for women with high-risk APS pregnancies, potentially opening the door to new treatment approaches.

Read the full article here: https://www.medscape.com/viewarticle/high-risk-pregnancies-women-aps-lupus-may-soon-see-upgrade-2026a100139m?

10/26/2026

Research report: Non-criteria antiphospholipid antibodies and pregnancy outcomes in recurrent pregnancy loss patients

A 2026 study published in Frontiers in Medicine examined whether non-criteria antiphospholipid antibodies (aPL) are associated with pregnancy complications in women experiencing recurrent pregnancy loss.

Researchers studied 247 women and found that about 38% tested positive for at least one non-criteria antibody, including anti-phosphatidylserine/prothrombin (aPS/PT) and anti-prothrombin antibodies.
Although adverse pregnancy outcomes were slightly more common in antibody-positive women (53.68%) than antibody-negative women (46.71%), the difference was not statistically significant. However, babies born to antibody-positive mothers had slightly lower birth weights.

Interestingly, women receiving more intensive medical treatment had fewer adverse pregnancy outcomes, although researchers could not determine whether treatment directly caused the improvement.

Key Takeaway: Non-criteria antiphospholipid antibodies are relatively common among women with recurrent pregnancy loss, but this study did not establish that these antibodies independently predict pregnancy complications.

The researchers emphasized the need for larger studies to better understand their clinical significance and whether additional antibody testing could improve pregnancy care.

Why This Matters for APS Patients
These findings highlight the complexity of APS-related pregnancy complications and the importance of continued research into antibodies not included in standard APS testing.

Importantly, the absence of a statistically significant association does not mean these antibodies are clinically irrelevant. The study was relatively small, and treatment differences may have influenced pregnancy outcomes.
This research also does not show that more intensive treatment benefits every patient.

Read the article in full here: https://bioengineer.org/research-report-non-criteria-antiphospholipid-antibodies-and-pregnancy-outcomes-in-recurrent-pregnancy-loss-patients/

10/26/2026

REMINDER: Daylight Saving Time ends Sunday, November 1st, 2026, at 2:00 AM, which is only one week away! This will be the best time to replace the batteries in your Smoke Detectors, Carbon Monoxide Detectors, and NOAA Weather Radio.

10/26/2026

10/26/2026

Credit to Lori’s Lupus and Beyond 💜 Medical Gaslighting Is Real!

Patients deserve to be heard, believed, and treated with dignity. Dismissing symptoms doesn’t make them disappear. Your pain is real, your voice matters, and advocating for your health is your right!

Listen to patients. Believe their experiences. Advocate for better care. 💜🩺

10/25/2026

Mum welcomes miracle baby thanks to medics

A mother diagnosed with Syndrome ( ) has welcomed her miracle baby after experiencing a devastating pregnancy .
Eve Sleigh lost her first son, Laith, after he was born prematurely at 25 weeks and developed . Following his death, testing revealed that Eve had APS, an condition associated with blood and pregnancy .

During her next pregnancy, Eve received specialized care through Birmingham Women's Hospital's Rainbow Clinic. Her treatment included blood-thinning injections, aspirin, and frequent ultrasounds to monitor her baby's development.

Despite treatment, Eve experienced placental complications, requiring delivery at 33 weeks. Her son, Kiyaan, was born weighing 3 pounds, 15 ounces and spent three days in neonatal intensive care.

Further testing revealed that Eve also had Chronic Histiocytic Intervillositis ( ), a rare inflammatory condition affecting the placenta.

Now five months old, Kiyaan is thriving at home. Eve credits the Rainbow Clinic's specialized medical care and emotional support with helping her through a difficult pregnancy.

Key Takeaway: This story highlights the importance of identifying APS, closely monitoring high-risk pregnancies, and providing coordinated medical and emotional support following pregnancy loss. While APS can cause serious pregnancy complications, appropriate treatment and specialized care can improve the chances of a successful pregnancy.

It is also a reminder that additional placental conditions may contribute to pregnancy complications, even when APS is being treated.

Read the full article at: https://bwc.nhs.uk/news/mum-welcomes-miracle-baby-thanks-to-medics-17890

10/24/2026

Would you like to see testing for ?

10/23/2026

This is your reminder, if you are on Hydroxychloroquine (Plaquenil) make sure to get your eye exams. These aren't just getting your regular eye exam, these are tests to look for damage to your retina.

Long-term use of hydroxychloroquine (Plaquenil) can cause retinal toxicity (hydroxychloroquine retinopathy), a condition where the medication damages the light-sensitive layer at the back of the eye.

10/21/2026

10 Posts Not to Miss This Week - Hemostasis Today

10 Posts Not to Miss This Week / Abdulla A. Damluji, Akshat Jain, anticancer drugs, Anticoagulation, Cesar Garrido, Christina Pohlman, Headlines, Health,